Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Return on Invested Capital (2016 - 2025)

Amicus Therapeutics' Return on Invested Capital history spans 13 years, with the latest figure at 7.22% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Invested Capital fell 730.0% year-over-year to 7.22%, compared with a TTM value of 7.22% through Dec 2025, down 730.0%, and an annual FY2025 reading of 7.44%, down 753.0% over the prior year.
  • Return on Invested Capital for Q4 2025 was 7.22% at Amicus Therapeutics, down from 0.15% in the prior quarter.
  • The five-year high for Return on Invested Capital was 0.7% in Q1 2025, with the low at 7.22% in Q4 2025.
  • Average Return on Invested Capital over 5 years is 0.53%, with a median of 0.27% recorded in 2021.
  • Biggest YoY gain for Return on Invested Capital was 83bps in 2025; the steepest drop was -730bps in 2025.
  • Tracing FOLD's Return on Invested Capital over 5 years: stood at 0.29% in 2021, then plummeted by -36bps to 0.4% in 2022, then surged by 64bps to 0.15% in 2023, then surged by 158bps to 0.08% in 2024, then tumbled by -8671bps to 7.22% in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Return on Invested Capital are 7.22% (Q4 2025), 0.15% (Q3 2025), and 0.06% (Q2 2025).